#USA #New York #Securities Law #Faruqi & Faruqi #MoonLake

Legal Investigation into MoonLake Immunotherapeutics

Faruqi & Faruqi, LLP, a prominent securities law firm in the United States, has initiated an investigation concerning potential claims relating to the investors of MoonLake Immunotherapeutics, a company actively engaging in the development of innovative treatments. Investors who have acquired MoonLake securities between March 10, 2024, and September 29, 2025, are being urged to discuss their legal rights and possible actions they can take.

Background of MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, publicly traded on the NASDAQ under the ticker MLTX, has become the focal point of a serious legal scrutiny. The ongoing investigation arises from the announcement made by the company on September 28, 2025, indicating that its recently developed treatment, referred to as SLK, failed to demonstrate effectiveness compared to an existing medication known as BIMZELX. This announcement resulted in a significant drop in the company's stock—by nearly 90%, closing at $6.24 per share following the revelation.

Allegations Against MoonLake

The investigation led by Faruqi & Faruqi highlights crucial allegations against MoonLake and its executive team regarding violations of federal securities laws. The concerns raised include claims that MoonLake provided misleading statements about SLK’s potential clinical benefits. Specific issues noted include:
1. Assertions regarding shared molecular targets between SLK and BIMZELX.
2. Misleading information claiming SLK's unique nanobody structure would yield clinical benefits superior to traditional monoclonal antibodies.
3. Unsupported claims about SLK's supposed improved tissue penetration yielding better efficacy in clinical settings.

These allegations suggest that the company's positive forecasts about SLK were unfounded and lacked reasonable basis, leading to investor losses.

Call for Investor Action

Senior Partner at Faruqi & Faruqi, James (Josh) Wilson, emphasizes the importance of contacting the firm for investors who suffered losses during the affected period. The deadline for interested investors to act and seek the designation of lead plaintiff in the class action case is set for December 15, 2025. This role includes guiding the litigation on behalf of all affected shareholders.

How to Participate

Affected investors now have the chance to engage in this legal process either by reaching out to the firm directly through the provided contact details or by opting to remain classified as an absent class member. Potential plaintiffs are encouraged to consult legal counsel and explore their options. Importantly, an investor's choice to take an active or passive role does not affect their ability to recover compensation should the plaintiff class succeed.

Further Information and Aurora of Transparency

Faruqi & Faruqi is dedicated to pursuing justice for shareholders and can provide legal representation to achieve this goal. The firm is reaching out to not only shareholders but also whistleblowers and former employees of MoonLake who may possess critical information about the company's communications and corporate practices.

To learn more about potential legal actions regarding MoonLake Immunotherapeutics or for assistance from Faruqi & Faruqi, individuals can access their website or contact Josh Wilson directly at the provided phone numbers. Timely communication is encouraged, given the nature of securities law and the specific deadlines at hand.

Conclusion

As the situation surrounding MoonLake continues to unfold, Faruqi & Faruqi stands at the forefront, ready to guide and represent those affected by the recent turmoil within the firm. The ongoing investigation signifies a critical opportunity for investors to reclaim their rights and explore all avenues for recovery.